APO RESEARCH · REPORT
Recombinant Proteins
Recombinant protein is a manipulated form of protein encoded by recombinant DNA, which has been cloned in a foreign expression system to supports the expression of the exogenous gene. This recombinant DNA construct can be used to manufacture large quantities of useful protein products. The recombinant DNA, usually the cDNA sequence of the target protein, is designed to be under the control of a well-characterized promoter to express the target protein within the chosen host cell to achieve high-level protein expression.
Product & engineering
Understand the product.
Recombinant protein is a manipulated form of protein encoded by recombinant DNA, which has been cloned in a foreign expression system to supports the expression of the exogenous gene. This recombinant DNA construct can be used to manufacture large quantities of useful protein products. The recombinant DNA, usually the cDNA sequence of the target protein, is designed to be under the control of a well-characterized promoter to express the target protein within the chosen host cell to achieve high-level protein expression.
Selected research
Industry Research
Recombinant Proteins Industry Research Report 2026
Market perspective
Recombinant protein is a manipulated form of protein encoded by recombinant DNA, which has been cloned in a foreign expression system to supports the expression of the exogenous gene. This recombinant DNA construct can be used to manufacture large quantities of useful protein products. The recombinant DNA, usually the cDNA sequence of the target protein, is designed to be under the control of a well-characterized promoter to express the target protein within the chosen host cell to achieve high-level protein expression.
Abcam PLC was the largest company in the global Recombinant Proteins market, with a revenue market share of 13% in 2018.
Top 5 companies occupied 40% of the market.
Read the full market overview
By region, Europe was the biggest region, with a revenue market share over 33%, and North America ranked 2. Asia-Pacific ranked 3, and its market grew fastest.
Report Scope
This report quantifies the global Recombinant Proteins market in terms of revenue (US$ million) and, where applicable, service volume (M USD), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/M USD) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Recombinant Proteins.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Recombinant Proteins Market by Company
Abcam PLC
R&D Systems
Miltenyi Biotec
Thermo Fisher Scientific
Sigma Aldrich Company
GE Healthcare
Lonza
Merck KGaA
ProSpec Tany TechnoGene
Eurogentec (Kaneka Corporation)
PeproTech
BPS Bioscience
Reprocell
GenScript Biotech Corporation
Abnova Corporation
Recombinant Proteins Segment by Type
Hormones
Growth Factors
Cytokines
Plasma Protein Factor
Recombinant Metabolic Enzymes
Immune Checkpoint Regulators
Others
Recombinant Proteins Segment by Application
Biopharmaceutical Companies
Academic and Research Institutes
Contract Research Organizations
Recombinant Proteins Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Proteins market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Proteins and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Proteins.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Recombinant Proteins companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Hormones
- Growth Factors
- Cytokines
- Plasma Protein Factor
- Recombinant Metabolic Enzymes
- Immune Checkpoint Regulators
- Others
Applications
- Biopharmaceutical Companies
- Academic and Research Institutes
- Contract Research Organizations
Companies covered
- Abcam PLC
- R&D Systems
- Miltenyi Biotec
- Thermo Fisher Scientific
- Sigma Aldrich Company
- GE Healthcare
- Lonza
- Merck KGaA
- ProSpec Tany TechnoGene
- Eurogentec (Kaneka Corporation)
- PeproTech
- BPS Bioscience
- Reprocell
- GenScript Biotech Corporation
- Abnova Corporation
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Recombinant Proteins by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Hormones
- 2.2.3 Growth Factors
- 2.2.4 Cytokines
- 2.2.5 Plasma Protein Factor
- 2.2.6 Recombinant Metabolic Enzymes
- 2.2.7 Immune Checkpoint Regulators
- 2.2.8 Others
- 2.3 Recombinant Proteins by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Biopharmaceutical Companies
- 2.3.3 Academic and Research Institutes
- 2.3.4 Contract Research Organizations
- 2.4 Assumptions and Limitations
3 Recombinant Proteins Breakdown Data by Type
- 3.1 Global Recombinant Proteins Historic Market Size by Type (2021-2026)
- 3.2 Global Recombinant Proteins Forecasted Market Size by Type (2027-2032)
4 Recombinant Proteins Breakdown Data by Application
- 4.1 Global Recombinant Proteins Historic Market Size by Application (2021-2026)
- 4.2 Global Recombinant Proteins Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Recombinant Proteins Market Perspective (2021-2032)
- 5.2 Global Recombinant Proteins Growth Trends by Region
- 5.2.1 Global Recombinant Proteins Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Recombinant Proteins Historic Market Size by Region (2021-2026)
- 5.2.3 Recombinant Proteins Forecasted Market Size by Region (2027-2032)
- 5.3 Recombinant Proteins Market Dynamics
- 5.3.1 Recombinant Proteins Industry Trends
- 5.3.2 Recombinant Proteins Market Drivers
- 5.3.3 Recombinant Proteins Market Challenges
- 5.3.4 Recombinant Proteins Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Recombinant Proteins Players by Revenue
- 6.1.1 Global Top Recombinant Proteins Players by Revenue (2021-2026)
- 6.1.2 Global Recombinant Proteins Revenue Market Share by Players (2021-2026)
- 6.2 Global Recombinant Proteins Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Recombinant Proteins Head Office and Area Served
- 6.4 Global Recombinant Proteins Players, Product Type & Application
- 6.5 Global Recombinant Proteins Manufacturers Established Date
- 6.6 Global Recombinant Proteins Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Recombinant Proteins Market Size (2021-2032)
- 7.2 North America Recombinant Proteins Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Recombinant Proteins Market Size by Country (2021-2026)
- 7.4 North America Recombinant Proteins Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Recombinant Proteins Market Size (2021-2032)
- 8.2 Europe Recombinant Proteins Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Recombinant Proteins Market Size by Country (2021-2026)
- 8.4 Europe Recombinant Proteins Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Recombinant Proteins Market Size (2021-2032)
- 9.2 Asia-Pacific Recombinant Proteins Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Recombinant Proteins Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Recombinant Proteins Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Recombinant Proteins Market Size (2021-2032)
- 10.2 South America Recombinant Proteins Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Recombinant Proteins Market Size by Country (2021-2026)
- 10.4 South America Recombinant Proteins Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Recombinant Proteins Market Size (2021-2032)
- 11.2 Middle East & Africa Recombinant Proteins Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Recombinant Proteins Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Recombinant Proteins Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Abcam PLC
- 12.1.1 Abcam PLC Company Information
- 12.1.2 Abcam PLC Business Overview
- 12.1.3 Abcam PLC Revenue in Recombinant Proteins Business (2021-2026)
- 12.1.4 Abcam PLC Recombinant Proteins Product Portfolio
- 12.1.5 Abcam PLC Recent Developments
- 12.2 R&D Systems
- 12.2.1 R&D Systems Company Information
- 12.2.2 R&D Systems Business Overview
- 12.2.3 R&D Systems Revenue in Recombinant Proteins Business (2021-2026)
- 12.2.4 R&D Systems Recombinant Proteins Product Portfolio
- 12.2.5 R&D Systems Recent Developments
- 12.3 Miltenyi Biotec
- 12.3.1 Miltenyi Biotec Company Information
- 12.3.2 Miltenyi Biotec Business Overview
- 12.3.3 Miltenyi Biotec Revenue in Recombinant Proteins Business (2021-2026)
- 12.3.4 Miltenyi Biotec Recombinant Proteins Product Portfolio
- 12.3.5 Miltenyi Biotec Recent Developments
- 12.4 Thermo Fisher Scientific
- 12.4.1 Thermo Fisher Scientific Company Information
- 12.4.2 Thermo Fisher Scientific Business Overview
- 12.4.3 Thermo Fisher Scientific Revenue in Recombinant Proteins Business (2021-2026)
- 12.4.4 Thermo Fisher Scientific Recombinant Proteins Product Portfolio
- 12.4.5 Thermo Fisher Scientific Recent Developments
- 12.5 Sigma Aldrich Company
- 12.5.1 Sigma Aldrich Company Company Information
- 12.5.2 Sigma Aldrich Company Business Overview
- 12.5.3 Sigma Aldrich Company Revenue in Recombinant Proteins Business (2021-2026)
- 12.5.4 Sigma Aldrich Company Recombinant Proteins Product Portfolio
- 12.5.5 Sigma Aldrich Company Recent Developments
- 12.6 GE Healthcare
- 12.6.1 GE Healthcare Company Information
- 12.6.2 GE Healthcare Business Overview
- 12.6.3 GE Healthcare Revenue in Recombinant Proteins Business (2021-2026)
- 12.6.4 GE Healthcare Recombinant Proteins Product Portfolio
- 12.6.5 GE Healthcare Recent Developments
- 12.7 Lonza
- 12.7.1 Lonza Company Information
- 12.7.2 Lonza Business Overview
- 12.7.3 Lonza Revenue in Recombinant Proteins Business (2021-2026)
- 12.7.4 Lonza Recombinant Proteins Product Portfolio
- 12.7.5 Lonza Recent Developments
- 12.8 Merck KGaA
- 12.8.1 Merck KGaA Company Information
- 12.8.2 Merck KGaA Business Overview
- 12.8.3 Merck KGaA Revenue in Recombinant Proteins Business (2021-2026)
- 12.8.4 Merck KGaA Recombinant Proteins Product Portfolio
- 12.8.5 Merck KGaA Recent Developments
- 12.9 ProSpec Tany TechnoGene
- 12.9.1 ProSpec Tany TechnoGene Company Information
- 12.9.2 ProSpec Tany TechnoGene Business Overview
- 12.9.3 ProSpec Tany TechnoGene Revenue in Recombinant Proteins Business (2021-2026)
- 12.9.4 ProSpec Tany TechnoGene Recombinant Proteins Product Portfolio
- 12.9.5 ProSpec Tany TechnoGene Recent Developments
- 12.10 Eurogentec (Kaneka Corporation)
- 12.10.1 Eurogentec (Kaneka Corporation) Company Information
- 12.10.2 Eurogentec (Kaneka Corporation) Business Overview
- 12.10.3 Eurogentec (Kaneka Corporation) Revenue in Recombinant Proteins Business (2021-2026)
- 12.10.4 Eurogentec (Kaneka Corporation) Recombinant Proteins Product Portfolio
- 12.10.5 Eurogentec (Kaneka Corporation) Recent Developments
- 12.11 PeproTech
- 12.11.1 PeproTech Company Information
- 12.11.2 PeproTech Business Overview
- 12.11.3 PeproTech Revenue in Recombinant Proteins Business (2021-2026)
- 12.11.4 PeproTech Recombinant Proteins Product Portfolio
- 12.11.5 PeproTech Recent Developments
- 12.12 BPS Bioscience
- 12.12.1 BPS Bioscience Company Information
- 12.12.2 BPS Bioscience Business Overview
- 12.12.3 BPS Bioscience Revenue in Recombinant Proteins Business (2021-2026)
- 12.12.4 BPS Bioscience Recombinant Proteins Product Portfolio
- 12.12.5 BPS Bioscience Recent Developments
- 12.13 Reprocell
- 12.13.1 Reprocell Company Information
- 12.13.2 Reprocell Business Overview
- 12.13.3 Reprocell Revenue in Recombinant Proteins Business (2021-2026)
- 12.13.4 Reprocell Recombinant Proteins Product Portfolio
- 12.13.5 Reprocell Recent Developments
- 12.14 GenScript Biotech Corporation
- 12.14.1 GenScript Biotech Corporation Company Information
- 12.14.2 GenScript Biotech Corporation Business Overview
- 12.14.3 GenScript Biotech Corporation Revenue in Recombinant Proteins Business (2021-2026)
- 12.14.4 GenScript Biotech Corporation Recombinant Proteins Product Portfolio
- 12.14.5 GenScript Biotech Corporation Recent Developments
- 12.15 Abnova Corporation
- 12.15.1 Abnova Corporation Company Information
- 12.15.2 Abnova Corporation Business Overview
- 12.15.3 Abnova Corporation Revenue in Recombinant Proteins Business (2021-2026)
- 12.15.4 Abnova Corporation Recombinant Proteins Product Portfolio
- 12.15.5 Abnova Corporation Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst